Atrial Septum Defect Closure

  • Jennifer Franke
  • Stefan C. Bertog
  • Horst SievertEmail author


Low complication rates of transcatheter atrial septum defect (ASD) closure and robust long-term results have resulted in a high acceptance of this method by physicians and patients alike. Consequently, this interventional technique has replaced open heart surgery as the standard therapeutic approach. All septal occluders available today are relatively easy to use by experienced operators and are available in different sizes to accommodate the highly variable ASD morphology and sizes. Careful patient selection and knowledge of specific implantation strategies for complex defects allow experienced operators to consider transcatheter ASD closure even in challenging cases.


  1. 1.
    Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890–900.CrossRefPubMedGoogle Scholar
  2. 2.
    Lindsey JB, Hillis LD. Clinical update: atrial septal defect in adults. Lancet. 2007;369(9569):1244–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23):2915–57.CrossRefPubMedGoogle Scholar
  4. 4.
    Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to develop guidelines on the Management of Adults with Congenital Heart Disease). Developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(23):e143–263.CrossRefPubMedGoogle Scholar
  5. 5.
    Bhatt AB, Foster E, Kuehl K, et al. Congenital heart disease in the older adult: a scientific statement from the American Heart Association. Circulation. 2015;131(21):1884–931.CrossRefPubMedGoogle Scholar
  6. 6.
    Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet. 2014;383(9932):1921–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Hufnagel CA, Gillespie JF. Closure of interauricular septal defects. Bull Georgetown Univ Med Cent. 1951;4(5):137–9.PubMedGoogle Scholar
  8. 8.
    Lewis FJ, Taufic M. Closure of atrial septal defects with the aid of hypothermia; experimental accomplishments and the report of one successful case. Surgery. 1953;33(1):52–9.PubMedGoogle Scholar
  9. 9.
    King TD, Mills NL. Nonoperative closure of atrial septal defects. Surgery. 1974;75(3):383–8.PubMedGoogle Scholar
  10. 10.
    King TD, Thompson SL, Steiner C, Mills NL. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA. 1976;235(23):2506–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. 2002;39(6):1061–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004;63(4):496–502.CrossRefPubMedGoogle Scholar
  13. 13.
    Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. 2005;45(8):1213–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Thomson JD, Qureshi SA. Device closure of secundum atrial septal defect's and the risk of cardiac erosion. Echo Res Pract. 2015;2(4):R73–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Silversides CK, Haberer K, Siu SC, et al. Predictors of atrial arrhythmias after device closure of secundum type atrial septal defects in adults. Am J Cardiol. 2008;101(5):683–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43(2):302–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Taaffe M, Fischer E, Baranowski A, et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder). Am J Cardiol. 2008;101(9):1353–8.CrossRefPubMedGoogle Scholar
  18. 18.
    El-Said HG, Moore JW. Erosion by the Amplatzer septal occluder: experienced operator opinions at odds with manufacturer recommendations? Catheter Cardiovasc Interv. 2009;73(7):925–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Hornung M, Bertog SC, Franke J, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J. 2013;34(43):3362–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol. 2004;93(4):426–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv. 2013;82(7):1123–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Loar RW, Johnson JN, Cabalka AK, et al. Effect of percutaneous atrial septal defect and patent foramen ovale device closure on degree of aortic regurgitation. Catheter Cardiovasc Interv. 2013;81(7):1234–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Scacciatella P, Marra S, Pullara A, et al. Percutaneous closure of atrial septal defect in adults: very long-term clinical outcome and effects on aortic and mitral valve function. J Invasive Cardiol. 2015;27(1):65–9.PubMedGoogle Scholar
  24. 24.
    Schoen SP, Boscheri A, Lange SA, et al. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale. Heart. 2008;94(7):844–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Wertman B, Azarbal B, Riedl M, Tobis J. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol. 2006;47(6):1226–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Smith BG, Wilson N, Richens T, Knight WB. Midterm follow-up of percutaneous closure of secundum atrial septal defect with Helex septal Occluder. J Interv Cardiol. 2008;21(4):363–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jennifer Franke
    • 1
  • Stefan C. Bertog
    • 1
    • 2
  • Horst Sievert
    • 1
    Email author
  1. 1.CardioVascular Center FrankfurtFrankfurtGermany
  2. 2.Department of Invasive CardiologyMinneapolis Veterans Affairs Medical CenterMinneapolisUSA

Personalised recommendations